SCHEMBL3933161

SCHEMBL3933161

CSc1nccc(N(C)c2cc(-c3ccccc3)c3nc[nH]c3c2)n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 1/20 0.34
▸ QPCT Q16769 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.32
▸ NPSR1 Q6W5P4 2/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ ADORA3 P0DMS8 1/20 0.31
▸ ADORA2A P29274 1/20 0.31
▸ ADORA1 P30542 1/20 0.31
▸ AKT1 P31749 2/20 0.30
▸ AKT2 P31751 2/20 0.30
▸ BRD4 O60885 2/20 0.30
▸ DCUN1D1 Q96GG9 1/20 0.30
▸ MET P08581 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ POLB P06746 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14395973 0.89 BRD4 (0.33) DPP4BRD4
SCHEMBL3925451 0.81 DPP4 (0.33) DPP4ADORA3ADORA2AADORA1
SCHEMBL3923592 0.80 DPP4 (0.37) DPP4KDM4ENPSR1MAPK1L3MBTL1
SCHEMBL3926834 0.78 LMNA (0.39) L3MBTL1BRD4ALDH1A1POLBHPGD
SCHEMBL14396494 0.75 MAPK8 (0.40) MAPK1ADORA2AADORA1AKT1AKT2
SCHEMBL5914335 0.75 IGF1R (0.41) ADORA2AADORA1AKT1AKT2MAPT
SCHEMBL14396352 0.75 SYK (0.36) MAPK1ALDH1A1MEN1NPC1RAB9A
SCHEMBL5320096 0.74 BRD4 (0.37) KDM4ENPSR1BRD4ALDH1A1POLB
SCHEMBL3924418 0.73 OGA (0.40) KDM4EL3MBTL1AKT1AKT2NPC1
SCHEMBL5260815 0.72 CSNK1E (0.39) KDM4ENPSR1MAPK1L3MBTL1DCUN1D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2041118-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen, Inc (US) 2009-04-01 — — EP disclosed
WO-2007114827-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2007-10-11 — — WO disclosed
WO-2007114827-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2007-10-11 — — WO disclosed
US-20060247263-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2006-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247263-A1 Substituted heterocyclic compounds and methods of use MAPT, IAPP, MYLK2 DPP4 1381/4885QPCT 2419/4885KDM4E 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback